Alpha Profiles · Company Profile

Lexeo Therapeutics, Inc.

Canonical company identity and public leadership record.

https://registry.alpha.ac/companies/lexeo-therapeutics-inc

Entity: Public listing published
Primary listing: NASDAQ: LXEO
Verification: Partially verified
Last reviewed: 2026-10-06T04:46:47.792621+00:00

Overview

Alpha's canonical identity and public leadership record for Lexeo Therapeutics, Inc..

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

10 public records

Eric Adler, M.D.

Chief Medical Officer and Head of Research

State: confirmed
Effective: Date not stated
Confidence: 94%
Evidence: LXEO executive roster sourceMay 3, 2026

Jenny R. Robertson, J.D.

Chief Legal Officer

State: confirmed
Effective: Date not stated
Confidence: 94%
Evidence: LXEO executive roster sourceMay 3, 2026

Jose Manuel Otero

Chief Operating Officer

State: confirmed
Effective: From Apr 30, 2026
Confidence: 94%
Evidence: LXEO DEF 14A executive officersApr 30, 2026

Jose Manuel Otero, Ph.D.

Chief Operating Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-193930Apr 30, 2026

Kyle Rasbach, Ph.D.

Chief Financial Officer

State: confirmed
Effective: Date not stated
Confidence: 94%
Evidence: LXEO executive roster sourceMay 3, 2026

Louis Tamayo

Chief Financial Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-193930Apr 30, 2026

Narinder Bhalla, M.D.

Chief Medical Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-193930Apr 30, 2026

Narinder P. Bhalla

Chief Medical Officer

State: confirmed
Effective: From Apr 30, 2026
Confidence: 94%
Evidence: LXEO DEF 14A executive officersApr 30, 2026

R. Nolan Townsend

Chief Executive Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001193125-26-193930Apr 30, 2026

Sandi See Tai, M.D.

Chief Development Officer

State: confirmed
Effective: Date not stated
Confidence: 94%
Evidence: LXEO executive roster sourceMay 3, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Oct 6, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.